ACIU - acimmune.com Long-Term Liabilities to Capital

The confirmed price history on this chart allows for an assessment of the impact of strict FDA oversight and massive R&D expenditures, where the figure stands at 0.09. AC Immune focuses its business on creating innovative dementia medications, which makes it resilient to market volatility. The company is actively expanding its portfolio of therapeutic solutions, leveraging the critical public need for the treatment of neurodegenerative pathologies.

This indicator compares liabilities with a maturity of more than one year against total equity to determine the company's degree of reliance on external long-term financing. By analyzing the long-term debt structure relative to equity, an investor can assess the extent to which AC Immune (ACIU) funds its neurodegeneration research through internal resources, confirming the issuer's financial stability when entering strategic partnerships.